Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-02-13
Butterfly Network, Inc.
Butterfly sells handheld ultrasound probes paired with cloud-connected subscriptions and workflow software for clinicians and health systems.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From handheld device to governed imaging workflow
A credible 5-year upside case requires enterprise standardization, higher recurring attach, and pricing that survives AI-driven seat deflation. The next re-score is gated by FY2026 guidance, margin trajectory, and runway clarity.

Analysis

Thesis
If Butterfly turns handheld ultrasound into a governed, EHR-integrated workflow (not a gadget), the probe becomes distribution and the cloud becomes the trust layer—supporting a shift from per-seat memberships to facility/outcome packaging, higher recurring mix, and non-linear enterprise rollouts despite incumbent bundling pressure.
Last Economy Alignment
AI makes image interpretation/training cheaper (demand tailwind) while shifting value to trusted evidence capture, compliance, and distribution; Butterfly has a hardware+cloud control point but must avoid getting bundled out by incumbents.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.3x (from 5 most recent analyses)
Reasoning
Butterfly’s credible path to 2–5x equity value is mix shift: more enterprise deployments, higher recurring attach, and packaging that survives “software-to-zero.” The upside is not just more probes—it’s becoming the compliance-grade system-of-record for point-of-care ultrasound evidence, with EHR-native documentation/billing hooks and facility-level contracts that reduce per-seat fragility. If that happens, the market can underwrite better retention and a higher-quality revenue stream than a pure device vendor.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is a timing trap: enterprise standardization and durable recurring attach may scale slower than cash consumption and product-cycle volatility. If incumbents win procurement via bundling and Butterfly can’t become the trusted evidence/workflow layer, the business remains a lower-multiple device vendor and equity value capture shifts to future financings rather than shareholders.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.30
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case